Autoantibodies in cancer: Prognostic biomarkers and immune activation

Kerstin Järås, Karen Anderson

Research output: Contribution to journalReview articlepeer-review

32 Scopus citations


The development of proteomic technologies that display a wide variety of antigenic structures has led to the identification of autoantibodies to cancer-derived tumor antigens. These autoantibodies have been detected in sera from patients with multiple cancer types, and are being evaluated as biomarkers for early cancer detection. It is not known whether these antibodies also contribute to active immune surveillance or even tumorigenicity of developing tumors. Here, we review which tumor antigen-specific antibodies are prognostic biomarkers of cancer outcome, and emerging proteomic methods for the isolation and cloning of these antibodies for potential molecular diagnostics and therapeutics.

Original languageEnglish (US)
Pages (from-to)577-589
Number of pages13
JournalExpert Review of Proteomics
Issue number5
StatePublished - Oct 2011


  • autoantibodies
  • cancer
  • clinical outcome
  • function
  • human monoclonal antibodies
  • prognosis
  • prognostic
  • recurrence
  • survival
  • therapeutic antibodies
  • tumor antigens

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology


Dive into the research topics of 'Autoantibodies in cancer: Prognostic biomarkers and immune activation'. Together they form a unique fingerprint.

Cite this